Q32 Bio Operating Expenses Growth & History (QTTB)
Q32 Bio's operating expenses was $36.8M for fiscal 2025.
View full Q32 Bio company overviewQ32 Bio annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $36.8M | −$29.3M | −44.28% |
| 2024 | 2024-12-31 | $66.1M | $24.5M | +58.88% |
| 2023 | 2023-12-31 | $41.6M | −$94.9M | −69.52% |
| 2022 | 2022-12-31 | $136.5M | $6.6M | +5.06% |
| 2021 | 2021-12-31 | $129.9M | −$3.0M | −2.29% |
| 2020 | 2020-12-31 | $133.0M | $21.4M | +19.13% |
| 2019 | 2019-12-31 | $111.6M | $46.4M | +71.05% |
| 2018 | 2018-12-31 | $65.2M | $35.6M | +120.01% |
| 2017 | 2017-12-31 | $29.7M | — | — |
Q32 Bio quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9.1M | −$53,000 | −0.58% |
| Q1 2026 | 2026-03-31 | $7.7M | −$4.5M | −36.85% |
| Q4 2025 | 2025-12-31 | $7.9M | −$6.7M | −45.90% |
| Q3 2025 | 2025-09-30 | $7.6M | −$11.2M | −59.73% |
| Q2 2025 | 2025-06-30 | $9.2M | −$8.7M | −48.82% |
| Q1 2025 | 2025-03-31 | $12.2M | −$2.6M | −17.62% |
| Q4 2024 | 2024-12-31 | $14.5M | $3.4M | +30.31% |
| Q3 2024 | 2024-09-30 | $18.8M | $9.2M | +94.82% |
| Q2 2024 | 2024-06-30 | $17.9M | $7.4M | +70.98% |
| Q1 2024 | 2024-03-31 | $14.8M | $4.5M | +43.83% |
| Q4 2023 | 2023-12-31 | $11.1M | −$24.1M | −68.42% |
| Q3 2023 | 2023-09-30 | $9.7M | −$24.0M | −71.31% |
| Q2 2023 | 2023-06-30 | $10.5M | −$18.6M | −64.00% |
| Q1 2023 | 2023-03-31 | $10.3M | −$28.1M | −73.14% |
| Q4 2022 | 2022-12-31 | $35.3M | $869,000 | +2.52% |
| Q3 2022 | 2022-09-30 | $33.7M | $1.3M | +4.10% |
| Q2 2022 | 2022-06-30 | $29.1M | −$3.6M | −11.09% |
| Q1 2022 | 2022-03-31 | $38.4M | $8.0M | +26.32% |
| Q4 2021 | 2021-12-31 | $34.4M | $3.6M | +11.84% |
| Q3 2021 | 2021-09-30 | $32.3M | $3.5M | +12.13% |
| Q2 2021 | 2021-06-30 | $32.7M | −$3.5M | −9.72% |
| Q1 2021 | 2021-03-31 | $30.4M | −$6.7M | −17.97% |
| Q4 2020 | 2020-12-31 | $30.8M | $4.7M | +17.84% |
| Q3 2020 | 2020-09-30 | $28.8M | −$2.9M | −9.11% |
| Q2 2020 | 2020-06-30 | $36.3M | $7.9M | +27.85% |
| Q1 2020 | 2020-03-31 | $37.1M | $11.7M | +46.02% |
| Q4 2019 | 2019-12-31 | $26.1M | $4.8M | +22.24% |
| Q3 2019 | 2019-09-30 | $31.7M | $14.5M | +84.07% |
| Q2 2019 | 2019-06-30 | $28.4M | $13.5M | +91.44% |
| Q1 2019 | 2019-03-31 | $25.4M | $13.6M | +114.74% |
| Q4 2018 | 2018-12-31 | $21.4M | $9.1M | +74.27% |
| Q3 2018 | 2018-09-30 | $17.2M | $10.6M | +158.63% |
| Q2 2018 | 2018-06-30 | $14.8M | $8.8M | +145.37% |
| Q1 2018 | 2018-03-31 | $11.8M | $7.1M | +152.05% |
| Q4 2017 | 2017-12-31 | $12.3M | — | — |
| Q3 2017 | 2017-09-30 | $6.7M | — | — |
| Q2 2017 | 2017-06-30 | $6.0M | — | — |
| Q1 2017 | 2017-03-31 | $4.7M | — | — |
Q32 Bio operating expenses trends
Over the last five fiscal years, Q32 Bio's operating expenses decreased from $133.0M to $36.8M, a change of −$96.1M. The latest reported quarter, Q2 2026, shows $9.1M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Q32 Bio source filings ↗